CSF3 and neutropenia: The block of questions on the prescribing habits included the routine usage of G-CSF prophylaxis, the management of low, intermediate and high-risk chemotherapy-induced afebrile neutropenia, and the systematical risk factor assessment in patients receiving chemotherapy with FN risk of 10–20% (intermediate-risk group).